Role of Radiation Therapy for Renal Tumors

Bhupesh Parashar; Kanhu Charan Patro; Michael Smith; Shruthi Arora; Dattatreyudu Nori; A. Gabriella Wernicke

doi:10.1055/s-0033-1363847

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2014; 31(01): 086-090
DOI: 10.1055/s-0033-1363847

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Radiation Therapy for Renal Tumors

Authors

Bhupesh Parashar

¹Stich Radiation Center, Weill Cornell Medical Center, New York, New York
Kanhu Charan Patro

²Mahatma Gandhi Cancer Hospital, Visakhapatnam, Andhra Pradesh, India
Michael Smith

¹Stich Radiation Center, Weill Cornell Medical Center, New York, New York
Shruthi Arora

¹Stich Radiation Center, Weill Cornell Medical Center, New York, New York
Dattatreyudu Nori

¹Stich Radiation Center, Weill Cornell Medical Center, New York, New York
A. Gabriella Wernicke

¹Stich Radiation Center, Weill Cornell Medical Center, New York, New York

Abstract

Renal cell carcinoma (RCC) is an aggressive malignancy that carries a poor prognosis, especially in patients presenting with advanced stage. Primary treatment for localized RCC is surgical resection however, a significant number of patients still develop locoregional and distant metastasis after curative resection. In metastatic disease, radiation therapy (RT) has been used for palliation routinely for brain and other extracranial lesions with respectable response rates. However, RT for primary RCC has questionable benefit. In this article, the authors discuss the evidence with regards to the role of RT in primary RCC either as a primary treatment, adjuvant treatment, or preoperatively to improve resection outcomes. In addition, novel RT techniques such as stereotactic body radiation therapy and its use in RCC management are also addressed. Finally, the authors discuss the techniques and doses of RT for primary RCC.

Keywords

renal - radiation - stereotactic - intensity-modulated radiation therapy - role

Full Text

References

References
1 Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 2013; 7: 139-148
2 Sun M, Thuret R, Abdollah F , et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011; 59 (1) 135-141
3 Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113 (1) 78-83
4 Cindolo L, Chiodini P, Gallo C , et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2008; 113 (1) 65-71
5 Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91 (2) 354-361
6 Zigeuner R, Hutterer G, Chromecki T , et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2010; 57 (1) 102-109
7 Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997; 80 (12, Suppl): 2519-2528
8 Otto U, Huland H, Baisch H, Klöppel G. Transplantation of human renal cell carcinoma into NMRI nu/nu mice. III. Effect of irradiation on tumor acceptance and tumor growth. J Urol 1985; 134 (1) 170-174
9 Kijima T, Koga F, Fujii Y, Yoshida S, Tatokoro M, Kihara K. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS ONE 2013; 8 (5) e64615
10 Frydenberg M, Gunderson L, Hahn G, Fieck J, Zincke H. Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies. J Urol 1994; 152 (1) 15-21
11 Gay HA, Michalski JM. Cancer of the kidney, renal pelvis, and ureter. In: Halperin EC, Wazer DE, Perez CA, Brady LW, , eds. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia, PA: LWW; 2008: 1403-1404
12 van der Werf-Messing B. Proceedings: Carcinoma of the kidney. Cancer 1973; 32 (5) 1056-1061
13 van der Werf-Messing B, van der Heul RO, Ledeboer RC. Renal adenocarcinoma; a prospective therapy study in Rotterdam [in Dutch]. Ned Tijdschr Geneeskd 1980; 124 (31) 1298-1303
14 Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 1977; 11 (3) 277-281
15 Stein M, Kuten A, Halpern J, Coachman NM, Cohen Y, Robinson E. The value of postoperative irradiation in renal cell cancer. Radiother Oncol 1992; 24 (1) 41-44
16 Kao GD, Malkowicz SB, Whittington R, D'Amico AV, Wein AJ. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology 1994; 193 (3) 725-730
17 Makarewicz R, Zarzycka M, Kulińska G, Windorbska W. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 1998; 45 (6) 380-383
18 Kjaer M, Iversen P, Hvidt V , et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987; 21 (4) 285-289
19 Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13 (5) 665-672
20 Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 2004; 27 (6) 646-648
21 Wersäll PJ, Blomgren H, Lax I , et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005; 77 (1) 88-95
22 Svedman C, Sandström P, Pisa P , et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006; 45 (7) 870-875
23 Svedman C, Karlsson K, Rutkowska E , et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008; 47 (8) 1578-1583
24 Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 2012; 110 (11 Pt B): E737-E743
25 Teh B, Bloch C, Galli-Guevara M , et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 2007; 3 (1) e6